Shield Therapeutics (GB:STX) has released an update.
Shield Therapeutics PLC has announced the immediate departure of CEO Greg Madison and the appointment of interim CEO Anders Lundstrom, who brings extensive US market experience from his tenure at pharmaceutical and biotech companies. The company expressed gratitude to Madison for his contributions, including a partnership with Viatris and the growth of their key product, ACCRUFeR®, which addresses iron deficiency. ACCRUFeR® is positioned as a unique oral iron therapy, with a novel mechanism and favorable clinical trial results, aiming to fulfill a significant unmet medical need.
For further insights into GB:STX stock, check out TipRanks’ Stock Analysis page.
